FDA approves IV maintenance dosing of Leqembi® (lecanemab-irmb) for the treatment of early Alzheimer's Disease in the US ...Middle East

STOCKHOLM, Jan. 27, 2025 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ STOCKHOLM: BIOA B) today announced that the U.S. Food and Drug Administration (FDA) has approved BioArctic's partner Eisai's Supplemental Biologics License Application (sBLA) for Leqembi as a once every four weeks...

Read More Details
Finally We wish PressBee provided you with enough information of ( FDA approves IV maintenance dosing of Leqembi® (lecanemab-irmb) for the treatment of early Alzheimer's Disease in the US )

Also on site :

• Brynn Whitfield Announces Exit From 'RHONY' After Two Seasons
• Pop Princess Covers Classic ‘70s Rock Hit: ‘This Is So Good’
• 'He knows where to find me,' Newsom responds to Trump administration arrest threat